Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Diabetic Foot

Human Stem Cell Institute, Russia

Status: Completed

Conditions: Ulcers Related to Diabetic Foot Syndrome

Treatments: Drug: Neovasculgen

Study type: Interventional

Funder types: Other

Identifiers

NCT02538705

NeoFoot Pilot Study

Details and patient eligibility

About

The purpose of this study is to determine whether pl-vegf165 (Neovasculgen) is effective in the treatment of ulcers related to diabetic foot syndrome

Full description

This is a open clinical trial assessing the therapeutic efficacy of pl-vegf165 (Neovasculgen) in treating ulcers related to diabetic foot syndrome. Each patient will undergo several intramuscular injections with a treatment dose of pl-vegf165 (Neovasculgen) in calf of affected extrimity.

Study participants at the first study visit will complete study questionnaires, their foots will be assessed clinically for ulceration. After this initial assessment, the patients will undergo intramuscular injections of pl-vegf165 (Neovasculgen) in a calf altered with ulcers due to diabetic foot syndrome.

At three month post-injection, the patient will complete study questionnaires, their foots will be assessed clinically for ulceration, and their foots will undergo non-invasive transcutaneous oximetry measurement. At six months post-injection, the patient will again complete study questionnaires, their foots will be assessed clinically for ulceration and will undergo non-invasive transcutaneous oximetry measurement.

Enrollment: 35 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• obtained voluntary informed consent for participation in the clinical study
• presence of diabetic foot syndrome
• presence at least one active ulcer at baseline

Exclusion criteria

• Any disease that can, in the opinion of the treating physician, affect the outcome of the study
• Patients with addictive disorders or substance abuse
• Pregnancy or nursing
• All other exclusion criteria listed in the summary of product characteristics (SmPC)

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

35 participants in 1 patient group

Neovasculgen

Experimental group

Treatment:

Drug: Neovasculgen